Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs Materials Select Sector SPDR Fund — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.41 (market cap $2.27B), while Materials Select Sector SPDR Fund trades at $49.6 (market cap $7.73B). The key difference: Materials Select Sector SPDR Fund is far larger — about 3.4× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Materials Select Sector SPDR Fund is more actively traded (13,681,146 versus 4,179,659). Which is the better fit depends on your goals.
| SLS | XLB | |
|---|---|---|
Market Cap | $2.27B | $7.73B |
Volume | 4,179,659 | 13,681,146 |
Sector | Health | — |
52-Week High | $15.46 | $53.67 |
52-Week Low | $1.39 | $42.23 |
Enterprise Value | $2.14B | — |
Typical Hold Time | — | 70 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLB trades at $49.49, up 1.04% with a bearish technical signal from moving averages. The materials ETF shows neutral oscillators but faces selling pressure with ADX indicators signaling strong trends. Recent news highlights sector concentration risks with chemicals comprising 49% of assets, while infrastructure and manufacturing trends provide support. The ETF remains below its 200-day moving average of $50.93, indicating technical weakness.
Outlook remains cautious as materials sector faces cyclical headwinds with limited upside after recent rebound. Investment opportunity exists in AI-resistant businesses and infrastructure exposure, but risks include heavy concentration in chemicals and moderate overvaluation in construction materials. Wall Street sentiment appears mixed with some analysts viewing current levels as fully valued.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
